Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery
Advanced Materials · 2024-05 · 36 (22)
DOI: 10.1002/adma.202303266 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Materials, online erschienen am 10.11.2023. Verfasst von Mingdi Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience …. Hauptthemen laut MEDLINE: Nanoparticles, Nucleic Acids, Lipids. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 417 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Strategic Priority Research Program of the Chinese Academy of Sciences.
Abstract (Originalsprache)
Lipid‐based nanoparticles (LBNPs) are currently the most promising vehicles for nucleic acid drug (NAD) delivery. Although their clinical applications have achieved success, the NAD delivery efficiency and safety are still unsatisfactory, which are, to a large extent, due to the existence of multi‐level physiological barriers in vivo. It is important to elucidate the interactions between these barriers and LBNPs, which will guide more rational design of efficient NAD vehicles with low adverse effects and facilitate broader applications of nucleic acid therapeutics. This review describes the obstacles and challenges of biological barriers to NAD delivery at systemic, organ, sub‐organ, cellular, and subcellular levels. The strategies to overcome these barriers are comprehensively reviewed, mainly including physically/chemically engineering LBNPs and directly modifying physiological barriers by auxiliary treatments. Then the potentials and challenges for successful translation of these preclinical studies into the clinic are discussed. In the end, a forward look at the strategies on manipulating protein corona (PC) is addressed, which may pull off the trick of overcoming those physiological barriers and significantly improve the efficacy and safety of LBNP‐based NADs delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China.
- Sino-Danish College, University of Chinese Academy of Sciences, Beijing, 100049, China.
- Sino-Danish Center for Education and Research, Beijing, 100049, China.
- The GBA National Institute for Nanotechnology Innovation, Guangzhou, 510700, China.
ORCID-Profile: Chunying Chen
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Strategic Priority Research Program of the Chinese Academy of Sciences
- Beijing Nova Program
- Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
Zitieren
APA
Hu, M., Li, X., You, Z., Cai, R., & Chen, C. (2024). Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery. Advanced Materials, 36(22). https://doi.org/10.1002/adma.202303266
Vancouver
Hu M, Li X, You Z, Cai R, Chen C. Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery. Advanced Materials. 2024;36(22). doi:10.1002/adma.202303266
BibTeX
@article{Hu2024,
author = {Hu, Mingdi and Li, Xiaoyan and You, Zhen and Cai, Rong and Chen, Chunying},
title = {Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {22},
doi = {10.1002/adma.202303266}
}
EUVIMED